Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Colleen Annesley, MD, Rebecca Gardner, MD, Ashley Wilson, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Qian Vicky Wu, PhD, Adam Brand, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2019) 134 (Supplement_1): 223.

https://doi.org/10.1182/blood-2019-131346

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance

Katherine Elizabeth Masih, BS, Rebecca Gardner, MD, Berkley Gryder, PhD, Abdelmaksoud Abdallah, BS, Justin Lack, PhD, Benjamin Stanton, PhD, Ashley Wilson, PhD, Sivasish Sindiri, MS, Young Song, PhD, Zachary Rae, BS, Michael Kelly, PhD, Wang Chaoyu, MS, Xinyu Wen, MS, Adam Cheuk, PhD, Jun Wei, PhD, Michael C. Jensen, MD, Javed Khan, MD, Rimas Orentas, PhD

Blood (2019) 134 (Supplement_1): 2744.

https://doi.org/10.1182/blood-2019-130796

Published: 2019

Journal Articles

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Corinne Summers, MD, Colleen Annesley, MD, Marie Bleakley, MBBS, PhD MMSc, Ann Dahlberg, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 967.

https://doi.org/10.1182/blood-2018-99-115599

Published: 2018

Journal Articles

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Francesco Ceppi, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Stephanie Rhea, BS, Isaac C. Jenkins, MS, Qian V. Wu, PhD, Wen Yang, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Rebecca Gardner, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2018-99-110164

Published: 2018

Journal Articles

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Colleen Annesley, MD, Rebecca Gardner, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4021.

https://doi.org/10.1182/blood-2018-99-112285

Published: 2018

Journal Articles

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Brakke, MS, Stephanie Rhea, BS, Roxana Hicks, BS, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, PhD, Daniel Li, PhD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4022.

https://doi.org/10.1182/blood-2018-99-117493

Published: 2018

Journal Articles

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Rebecca Gardner, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Kaelin Crews, Lauren Huang, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Karen Spratt, PhD, Josh Gustafson, PhD, Adam Johnson, PhD, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 278.

https://doi.org/10.1182/blood-2018-99-113126

Published: 2018

Journal Articles

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Julie Rivers, MD, Colleen Annesley, MD, Corinne Summers, MD, Olivia Finney, PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2018-99-113744

Published: 2018

Journal Articles

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

Corinne Summers, MD, Alexandra Grier, Rebecca Gardner, MD, Colleen Delaney, MD MSc, Michael C Jensen, MD

Blood (2016) 128 (22): 1159.

https://doi.org/10.1182/blood.V128.22.1159.1159

Published: 2016

Journal Articles

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Smithers, MS, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Christopher Brown, Stephanie Mgebroff, MS, Catherine Lindgren, Karen Spratt, PhD, Assaf Oron, PhD, Daniel Li, PhD, Marie Bleakley, MDPhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 219.

https://doi.org/10.1182/blood.V128.22.219.219

Published: 2016

Journal Articles

Creation of the First Non-Human Primate Model That Faithfully Recapitulates Chimeric Antigen Receptor (CAR) T Cell-Mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity Following B Cell-Directed CAR-T Cell Therapy

Agne Taraseviciute, MD PhD, Leslie Kean, MD PhD, Michael C Jensen, MD

Blood (2016) 128 (22): 651.

https://doi.org/10.1182/blood.V128.22.651.651

Published: 2016

Journal Articles

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rebecca Gardner, MD, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Julie Rivers, MD, Juliane Gust, MD, Katherine Tarlock, MD, Todd M Cooper, DO, Navin R. Pinto, MD, Olivia Finney, PhD, Hannah Smithers, MS, Assaf Oron, PhD, Daniel Li, PhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 586.

https://doi.org/10.1182/blood.V128.22.586.586

Published: 2016

Journal Articles

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 3773.

https://doi.org/10.1182/blood.V126.23.3773.3773

Published: 2015

Journal Articles

Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab

Gregory A. Rufener, Philip Olsen, Sang Yun Lee, PhD, Michael C Jensen, MD, Ajay K. Gopal, MD, Barbara Pender, MS, Damian J. Green, MD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Oliver W Press, MD PhD, Brian G. Till, MD

Blood (2015) 126 (23): 4428.

https://doi.org/10.1182/blood.V126.23.4428.4428

Published: 2015

Journal Articles

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Leslie Popplewell, MD, Xiuli Wang, PhD, Araceli Naranjo, BS, Suzette Blanchard, PhD, Jamie Wagner, BS, ChingLam Wong, BS, Ryan Urak, MS, Wen-Chung Chang, MS, Samer K Khaled, MD, Tanya Siddiqi, MD, Elizabeth E. Budde, MD PhD, Jingying Xu, PhD, Brenda Chang, BS, Sandra H. Thomas, PhD, Stanley R. Riddell, MD, Christine Brown, PhD, Michael C Jensen, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 930.

https://doi.org/10.1182/blood.V126.23.930.930

Published: 2015

Journal Articles

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Cameron J Turtle, MBBS, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Laila-Aicha Hanafi, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 184.

https://doi.org/10.1182/blood.V126.23.184.184

Published: 2015

Journal Articles

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

Rebecca A Gardner, MD, Julie R Park, MD, Karen S Kelly-Spratt, PhD, Olivia Finney, PhD, Hannah Smithers, Virginia Hoglund, Christopher Brown, Stephanie Mgebroff, MS, Catherine G. Lindgren, Assaf P Oron, PhD, Marie Bleakley, MD, Michael C Jensen, MD

Blood (2014) 124 (21): 3711.

https://doi.org/10.1182/blood.V124.21.3711.3711

Published: 2014

Journal Articles

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

Cameron J Turtle, MBBS, PhD, Daniel Sommermeyer, PhD, Carolina Berger, MD, Michael Hudecek, MD, David M Shank, Natalia N Steevens, BS, Tanya M Budiarto, BSc, Mandana Karimi, MS, Colette N Chaney, RN, Anna Marie DeVito, RN, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R Riddell, MD, David G Maloney, MDPhD

Blood (2014) 124 (21): 384.

https://doi.org/10.1182/blood.V124.21.384.384

Published: 2014

NARROW

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Creation of the First Non-Human Primate Model That Faithfully Recapitulates Chimeric Antigen Receptor (CAR) T Cell-Mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity Following B Cell-Directed CAR-T Cell Therapy

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only